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P U B L I S H E D B Y E L S E V I E R I N C .LETTERS TO THE EDITORClosure of Incompletely
Surgically-Ligated Left Atrial
Appendage in Reducing
Stroke Risk
We read with great interest the Image in Intervention by Matsu-
moto et al. (1), published in the February 2013 issue of JACC:
Cardiovascular Interventions. In it, the authors describe a procedure
for percutaneous endocardial occlusion of incompletely surgically
ligated left atrial appendage (ISLL) using a septal occluder device
guided by transesophageal echocardiography (TEE) and angio-
graphy in a patient with atrial ﬁbrillation (AF) previously treated
with a surgical maze procedure, mitral and tricuspid valve repair,
and attempted surgical ligation of the left atrial appendage. In
addition, they argue that the proposed approach can “reduce the
risk of thromboembolism and stroke.”
Similarly, our group has recently published a paper on the safety
and feasibility of this technique (2). Although the clinical signiﬁ-
cance of ISLL warrants further investigation, it is believed to be
associated with an increased risk of thromboembolism. Moreover,
it is believed that ISLL may actually be worse than no occlusion at
all, given that reduced blood ﬂow in and out of a “stenotic” left
atrial appendage may in fact promote a higher risk of thrombus
formation inside this structure (3). Consistent with this, 3 patients
in our series presented with an early embolic event following ISLL
despite a CHADS2 score 1 and antiplatelet therapy. In addition,
we have observed an inverse relationship between embolic stroke
risk and the size of the ISLL neck diameter in our patients.
We, too, have not observed any embolic events in our small
cohort of AF patients who underwent percutaneous endocardial
ISLL occlusion, subsequently off oral anticoagulation therapy,
during 8  2 months of follow-up. Nevertheless, we have remained
cautious in offering hasty conclusions regarding long-term stroke
risk reduction through such an approach. An important element
that needs to be taken into consideration is the underlying disease
substrate. That is, although atrial thrombi likely originate inside the
left atrial appendage in nearly 90% of patients with nonvalvular AF,
the same is true for <50% of patients with valvular AF, as shown in
a recent systematic review of 34 studies (4). Hence, ﬁrm conclu-
sions regarding stroke risk reduction in the setting of AF and
cardiac valvular pathology derived purely on the basis of a single
case report seems premature.
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We appreciate the comments of Drs. Aryana and d’Avila regarding
our paper “Transcatheter Left Atrial Appendage Closure after
Incomplete Surgical Ligation” (1) and their own experience in
similar circumstances (2). Great minds do think alike.
We completely agree that in patients with valvular atrialﬁbrillation
(AF), the substrate is different, withw44% of thrombus in the left
atrial appendage (LAA) (3). However, the quoted cohort composed
almost entirely of patients with rheumatic mitral stenosis, much
different from our patient, who underwent a successful surgical mitral
valve repair for nonrheumatic mitral regurgitation. The patient was
left with only minor residual mitral regurgitation after the repair.
We also agree with the authors that an incomplete surgical closure
with a “stenotic” oriﬁce could promote blood stagnation, but when
coupled with reduced LAA ﬂow velocities from AF, the thrombo-
embolism risk maybe further accentuated. In the prospective,
randomized clinical trial of the Watchman device (Atritech, Inc.,
Minneapolis, Minnesota), a residual gap >5 mm is considered an
unsuccessful closure, requiring continuation of the patient’s anti-
coagulation (warfarin) (4). Therefore, we believe that if the original
intent is to performLAAexclusion and the risk of thromboembolism
is unacceptable, “the residual communication secondary to incom-
plete surgical ligation can be closed percutaneously to reduce the risk
of thromboembolism and stroke.”
We report this case because it demonstrates a relatively simple
solution and a clinically feasible approach to treat patients who have
a residual LAA to left atrial communication after surgical ligation
of the LAA. Additional clinical studies including of a large
numbers of patients will be necessary to better elucidate whether
the treatment approach we have shown to be feasible will in fact
decrease thromboembolic complications. We appreciate the authors
and editor for giving us an opportunity to clarify our statement.
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